Gennady Bratslavsky, MD, to lead cancer clinical trial consortium
Gennady Bratslavsky, MD, professor
“Such recognition is a reflection a great success of our Urology Department and our university,” said Julio Licinio, MD,
Created, owned and operated by its members, the SUO-CTC is a clinical research investigator network of more than 180 clinical sites in the U.S. and Canada. This national alliance of leading academic and
SUO-CTC pursues clinical trials, in concert with sponsors, to investigate therapeutic interventions which address urological cancers including, but not restricted to prostate, bladder, or kidney cancers. Together with industry, the SUO-CTC offers enhanced research options for ultimately delivering
Identifying relevant targets and managing clinical trials is increasingly complex. In the past, medical oncologists investigated a steady stream of drugs from the NCI for the conduct of phase II trials based primarily on endpoints defined by
The SUO Clinical Trials Consortium (SUO-CTC) fills the need for dedicated expertise and clinical input into the design of urology focused clinical trials and patient recruitment. Additionally, the SUO-CTC takes primary responsibility for delivery (i.e., reporting from supporting information systems) of clinical and translational research data to the Society of Urologic Oncology and the academic community at large.
SUO-CTC president’s post is a two- year term, which is renewable once for a total of four years.